Speculative Biotech With Big Upside Potential [Details Inside!]

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

SPECIAL OPPORTUNITIES We have a message from Ray Blanco at Paradigm Press. In it, he talks about a tiny stock that he expects to soar... SOON. We thought you may be interested in what he has to say... - Rachel Gearhart, Associate Publisher Speculative Biotech With Big Upside Potential [Details Inside!] Reader, Ray Blanco here. I'm writing to you today because a speculative biotech stock has just crossed my desk – and my research shows this company has explosive upside potential in the next 12 months. It all has to do with this patent which you can see in my hands here: You see, arthritis is one of the biggest and most common diseases in America... It impacts 54 million Americans, or about 26% of the adult population. And with an aging population, that number skyrockets every year. Which is why the market for arthritis treatments is projected to hit a staggering $30.4 billion by 2025... By 2030, it's set to go even higher. And this patent could be the solution tens of millions of Americans have been waiting for. It could mean the beginning of the end of arthritis. It could also mean the most profitable investment of your lifetime. Click here now for all of the details. To a bright future, Ray Blanco Chief Technology Officer, Paradigm Press You are receiving this email as a part of your membership in The Oxford Club. Oxford Club Special Opportunities is published by The Oxford Club. To unsubscribe from opportunity based emails like this one, click here. Please note that this will not impact the fulfillment of your subscription in any way.. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist The Oxford Club Special Opportunities © 2023 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.